The first 48 hours after the injection

Inside the joint, the process begins before you have even left the clinic room. ChondroFiller's collagen solution sets into a firm gel within three to five minutes of placement, bonding with the body's natural fibrin to anchor itself within the cartilage defect. Nothing has been implanted surgically — the treatment is an ultrasound-guided outpatient injection, and patients leave the same day without theatre admission or general anaesthetic.

Once the scaffold is in place, a process called acellular matrix-induced chondrogenesis gets under way. The collagen framework is not a filler in the conventional sense; it contains no cells of its own. Instead, it acts as a biological scaffold — a structured environment that draws the patient's own progenitor cells in from the surrounding synovium and subchondral bone. The repair that follows is driven by the body's own biology, with the scaffold providing the architecture for that process to occur in an organised way.

Some mild local discomfort, swelling, or stiffness over the first 24 to 48 hours is normal and is simply the joint responding to the procedure. More vigorous loading, however, is a different matter. A 2024 biomechanical study found that the scaffold carries initial mechanical instability under cyclic loading — meaning that full weight-bearing too early risks disturbing the gel before it has had time to stabilise. That finding is the scientific basis for the movement guidance that follows in the first weeks of recovery.

Weeks 1–6: protecting what has been placed

The six weeks that follow the injection are defined by one principle: give the scaffold the conditions it needs to integrate before asking it to bear load. Clinical guidance is consistent — limited weight-bearing, controlled range of motion, and no high-impact activity during this window. These are not generic precautionary measures; they reflect the biological reality of what is happening inside the joint at this stage.

Even in the first fortnight, repair is measurably under way. A 2025 ex vivo model recorded a 2.4-fold increase in DNA content within ChondroFiller-treated defects by day 14 — a direct indicator that the patient's own cells are migrating into the scaffold and beginning organised tissue formation. The activity is real and progressive, even though it produces no noticeable change in how the joint feels.

That gap between biological progress and perceived change is worth understanding clearly. MRI scoring at four weeks — using the validated MOCART system — recorded a mean value of 65.3 in a 2016 randomised controlled trial. That figure represents a scaffold that is present, visible, and consolidating, but not yet mature repair tissue. Patients who expect pain relief at this early stage may interpret its absence as a sign that something has gone wrong. It has not: the process is working, but at a cellular level that necessarily precedes any structural or symptomatic shift.

For most patients, this Protect phase lasts approximately four to six weeks. The movement restrictions are purposeful and time-limited — their aim is to safeguard scaffold integration, not to enforce rest as an end in itself. The phase that follows marks a deliberate, graduated return to activity.

Weeks 6–12: rebuilding strength and movement

Around week six, the emphasis shifts from protection to progressive rebuilding. Structured physiotherapy begins, and two activities are typically introduced first: cycling and swimming. Both allow graduated loading of the joint without the impact forces that could disturb the still-consolidating scaffold — the same biomechanical logic that shaped the Protect phase continues to govern the pace at which activity increases.

The most encouraging development in this window is symptomatic. Both the 2016 randomised controlled trial and a 2024 knee cohort study recorded statistically significant improvements in IKDC and Lysholm functional scores by the three-month mark — well before the point at which MRI confirms structural maturity. Patients who notice meaningful reductions in pain and improved movement during weeks 6–12 are not experiencing a placebo effect; clinical evidence supports early functional gain as a characteristic feature of this phase, not an anomaly.

Symptom improvement does run ahead of what imaging will show at this stage. The repair process continues throughout, even as the patient feels considerably better. Function returning before the scan catches up is the expected sequence — not a reason for concern, and not a signal that recovery is complete.

Individual variation is real and worth acknowledging. Small-joint pathways — a wrist injection, for example — may reach and progress through the Strengthen phase noticeably faster than large weight-bearing joints such as the knee or hip, where full loading demands more tissue maturity. A physiotherapist familiar with cartilage scaffold rehabilitation will calibrate the programme to the joint involved and the patient's rate of response.

Months 3–6: function stabilises as repair continues

By the time most patients reach the three-month mark, the early functional gains described in the Strengthen phase have typically settled into a more stable range — and evidence suggests that stability continues through to around six months. A 2024 knee cohort study (17 patients, 12-month follow-up) found no statistically significant difference in IKDC or Lysholm scores between the six- and twelve-month assessments (p>0.05). The functional improvement that accumulated during weeks six to twelve tends to hold rather than continuing to climb, and this consolidation is the defining feature of months three to six.

That plateau in symptom scores is not a signal of stagnation. Structural maturation — the ongoing replacement of the collagen scaffold with the patient's own organised tissue — continues well beyond the point at which questionnaire scores level off. The biology is still active; what has changed is that earlier functional gains have settled into a reliable baseline rather than advancing further. Most patients in this phase find that daily activities, light occupational demands, and low-impact sport are increasingly accessible, with sport-specific movements introduced gradually under physiotherapy guidance.

For patients in physically demanding roles, or those who want objective confirmation of progress beyond symptom scores, structured gait assessment or repeat imaging review at the treating clinic can provide measurable markers that questionnaires alone cannot capture.

One important caveat: those with advanced osteoarthritis — Tönnis grade 2 or 3 — may not follow this standard curve. A hip cohort study found that patients in this OA category showed poor results at three to five years, which underlines why a thorough pre-treatment assessment remains essential to identifying who is most likely to benefit.

Months 6–12: structural maturation and return to sport

Imaging tells a clear story across this period. MRI MOCART scores — which in the early consolidating phase sit well below 80 — climb to a mean of 81.6 by twelve months in the 2016 randomised controlled trial, with independent European series confirming final values of 81.6 to 84.3. Those numbers translate to greater than 80% defect filling and good peripheral tissue integration: the structural benchmarks that indicate the scaffold has done its primary job. The twelve-month scan is not a picture of completed remodelling, but it does reflect repair tissue that is sufficiently organised to support higher-demand activity in most patients.

On the clinical side, the headline figure is an IKDC improvement of approximately 30 points over twelve months — consistently seen across four independent knee studies and exceeding the established minimum clinically important difference of 16.7 points. Crucially, this gain persists. Jerosch and colleagues recorded a mean improvement of 32.4 points still intact at three-year follow-up, which gives patients reasonable grounds to expect that the functional benefit is durable rather than transient.

Return to sport sits within this window, but it is a decision rather than a date. The treating consultant weighs functional scores, imaging findings, joint type, and the specific demands of the activity before clearing a patient for higher-impact sport. A knee patient returning to recreational football faces different load demands from a hip patient returning to cycling, and the programme reflects that. Most patients in this phase are progressing toward sport under physiotherapist supervision, with full clearance confirmed once both the subjective scores and the clinical picture support it.

Beyond twelve months: full integration and long-term outlook

Somewhere between twelve and twenty-four months, the collagen scaffold is fully resorbed. This matters to patients who worry about foreign material remaining in the joint: there is none. What fills the original defect by this point is the patient's own organised repair tissue, laid down progressively by progenitor cells recruited into the scaffold during the earliest weeks. The matrix was temporary; the repair tissue is not.

The durability data, while drawn from small cohorts, is encouraging. A hip arthroscopy series with follow-up of twelve to sixty months found 17 of 21 evaluable patients achieving good or excellent outcomes on MRI cartilage healing assessment at three to five years. IKDC improvements of approximately 30 points in knee patients — documented across multiple independent studies — remained intact at three-year follow-up in data reported by Jerosch and colleagues. Individual trajectories vary, and the study populations remain small; what the published evidence supports is a pattern of sustained benefit, not a guarantee for any one patient.

The clearest limit in the data is patient selection. Patients with advanced osteoarthritis — Tönnis grade 2 or 3 — consistently show poorer long-term results, a recognised boundary that reflects the repair cycle's dependence on a joint that retains meaningful structural integrity beyond the focal defect itself.

Patients wondering whether their situation falls within that boundary can be assessed without a GP referral via mskdoctors.com. The more important question to bring to that appointment is whether the individual joint and activity goals match the conditions under which the evidence is strongest — and answering that takes a clinical assessment rather than a published average.

1. [1] Ex Vivo Osteochondral Biomimetic Platform for Cartilage Regeneration Investigation. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
2. [2] Implantation of ChondroFiller Liquid® as a Scaffold for Chondral Lesions of the Knee Joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Controlled, Randomized Multicenter Study: ChondroFiller Liquid vs Microfracturing — Knee Focal Cartilage Defects. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
4. [4] Arthroscopic Utilization of ChondroFiller Gel for Hip Articular Cartilage Defects: 12–60 Month Follow-Up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002